BTG plc (BTG) Upgraded by Numis Securities Ltd to “Buy”
BTG has been the topic of several other reports. Deutsche Bank AG reiterated a buy rating on shares of BTG plc in a research report on Friday, October 7th. JPMorgan Chase & Co. reiterated a neutral rating on shares of BTG plc in a research report on Friday, September 9th. Stifel Nicolaus lowered shares of BTG plc to a hold rating in a research report on Thursday, July 14th. Finally, Jefferies Group lifted their target price on shares of BTG plc from GBX 840 ($10.24) to GBX 860 ($10.48) and gave the company a buy rating in a research report on Wednesday, June 29th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of GBX 822.86 ($10.03).
Shares of BTG plc (LON:BTG) opened at 693.50 on Monday. The stock’s market capitalization is GBX 2.66 billion. BTG plc has a 12-month low of GBX 504.00 and a 12-month high of GBX 739.50. The firm’s 50-day moving average is GBX 640.19 and its 200 day moving average is GBX 643.90.
In related news, insider Soderstrom,Rolf sold 74,327 shares of the business’s stock in a transaction that occurred on Thursday, July 21st. The shares were sold at an average price of GBX 676 ($8.24), for a total transaction of £502,450.52 ($612,371.14).
BTG plc Company Profile
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Stock Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related stocks with our FREE daily email newsletter.